Exclusive Summary

• - Long off-patent cytotoxic; fully genericized globally with stable, durable demand
• - Dual oncology-immunology use: ~20M new cancer cases/year plus severe AAV/LN patients requiring IV cyclophosphamide
• - WHO EML listed; remains guideline-endorsed as first-line/induction backbone in DLBCL, breast cancer, AAV, and LN
• - Crowded market but periodic sterile injectable shortages; US registration plus 500mg/1g/2g portfolio enables “reliable supply + low waste” differentiation
• - Distribution-ready asset for rapid tender/hospital access, delivering substantial savings versus originators